Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Anebulo Pharmaceuticals ( (ANEB) ) has shared an announcement.
On February 5, 2026, Anebulo Pharmaceuticals’ board approved the voluntary delisting of the company’s common stock from the Nasdaq Capital Market and the subsequent deregistration of its shares with the U.S. Securities and Exchange Commission, a move publicly announced in a press release dated February 6, 2026. While the company remains in compliance with Nasdaq listing standards, the board concluded that the costs and administrative burdens of being a publicly listed, SEC-reporting company outweigh the benefits, especially as it focuses resources on advancing its lead selonabant program. The delisting is expected to become effective on February 27, 2026, after the planned filing of Form 25, with a Form 15 to be filed around the same date to terminate SEC registration and suspend periodic reporting obligations, after which trading in Anebulo’s shares would be limited to private transactions and potentially over-the-counter markets, altering liquidity and transparency for existing shareholders.
The most recent analyst rating on (ANEB) stock is a Sell with a $0.91 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
Spark’s Take on ANEB Stock
According to Spark, TipRanks’ AI Analyst, ANEB is a Underperform.
The score is driven primarily by weak financial fundamentals (no revenue, continuing losses, and persistent cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate actions provide only modest support, while valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on ANEB stock, click here.
More about Anebulo Pharmaceuticals
Anebulo Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for acute cannabis-induced toxicity. Its lead product candidate, selonabant, a competitive CB1 receptor antagonist, has completed a Phase 2 trial in adults with acute cannabinoid intoxication using an oral formulation, while the company is now prioritizing an intravenous formulation aimed at pediatric patients, with a Phase 1 single-ascending-dose study of IV selonabant initiated in September 2025.
Average Trading Volume: 69,973
Technical Sentiment Signal: Sell
Current Market Cap: $39.03M
See more insights into ANEB stock on TipRanks’ Stock Analysis page.